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OBJECTIVES: A recent 12-week phase 2 randomized
clinical trial evaluated the hemoglobin (hgb) response
rates (% patients with hgb increase ≥2g/dL from base-
line, in the absence of RBC transfusion) of four different
dosing schedules of darbepoetin alfa administered every
other week (q2w) to anemic patients with solid tumors
receiving chemotherapy. A randomized group of epoetin
alfa patients (40,000U/wk; dose escalated to 
60,000U/wk at 6 weeks for inadequate response) was the
active control. Recent literature indicates the mean dura-
tion of anemia treatment with epoetin alfa for cancer
patients on chemotherapy to be 16 to 24 weeks. We
designed a 20-week model to evaluate the cost-
effectiveness of 3.0mcg/kg Q2wk of darbepoetin alfa (n
= 33) compared to epo (n = 32). METHODS: Average
wholesale prices (AWPs) of the 2 drugs in United States
were used as the sole cost driver over the expected 20-
week anemia treatment period. Response rates at week
12 were used as the efﬁcacy measures for the two thera-
pies. RESULTS: Mean cumulative 20-week doses per
patient for darbepoetin alfa and epoetin alfa were esti-
mated to be 2,100mcg (assuming mean patient weight =
70kg) and 844,800U, respectively. Compared to the esti-
mated 20-week cost of epoetin alfa therapy, darbepoetin
alfa was estimated to be $800 less per patient (For the
12-week trial duration, darbpoetin alfa was about $380
cheaper). The response rates at the end of week 12 were
found to be similar (60%, with similar conﬁdence inter-
vals) for the 2 therapies. Smaller percent patients (3%
versus 7%) required RBC transfusions in darbepoetin alfa
group. Cost-effectiveness ratio (cost per % patients with
hgb response) was superior for darbepoetin alfa ($17,465
versus $18,812). CONCLUSIONS: Compared to stan-
dard practice epoetin alfa therapy, 3.0mcg/kg Q2wk dar-
bepoetin alfa provides a less expensive and cost-effective
alternative to treat cancer patients with chemotherapy-
induced anemia.
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Clinical trial health outcome data intended for the pur-
poses of economic evaluation must be capable of being
represented by a single, summary index. When beneﬁts
are to be estimated in terms of quality-adjusted life 
years that index needs to represent social preference
weights/utilities. However clinical trials often fail to
include utility-weighted measures in their protocols.
OBJECTIVE: To describe the strategic options available
to the researchers’ facing the task of deriving a utility
weighted index from a condition speciﬁc measure, using
the FACT-L as a case study. METHODS: The FACT-L 
is a widely used instrument that deﬁnes health-related
quality of life in terms of four dimensions: physical,
social, emotional and functional well-being. As far as 
is known, utility weights for the items/levels within the
FACT-L have not so far been published. The complexity
of the FACT-L makes it impossible to estimate utility
weights using traditional MAUT methods. Hence the sim-
pliﬁcation of the descriptive system is an essential pre-
requisite. Two separate strategies do this were adopted,
based ﬁrstly on the analysis of pre-existing responses on
the FACT-L, obtained in a clinical study of 431 patients
with non-small cell lung cancer and secondly on the
results of ﬁve qualitative interviews with oncologists
experienced in the use of FACT-L were performed.
RESULTS: The factor analytic approach yield limited
scope for item reduction although a more efﬁcient clus-
tering of items within dimensions was achieved. The qual-
itative review produced greater scope for simpliﬁcation 
of the descriptive system. CONCLUSIONS: An efﬁcient
subset of FACT-L items that have clinical descriptive
salience can be achieved as a preliminary to the estima-
tion of item/level utility weights.
PCN19
EXAMINING PREFERENCES AND TIME-
TRADE-OFF UTILITY FOR GEMCITABINE PLUS
CISPLATIN IN THE TREATMENT OF BLADDER
CANCER:A SURVEY USING DISCRETE CHOICE
CONJOINT ANALYSIS IN THE UK
Brown A1, Aristides M1, FitzGerald P2, Davey P2, Bhalla S3,
Kielhorn A3
1M-TAG Limited, London, United Kingdom; 2M-TAG Pty Ltd,
Sydney, Australia; 3Eli Lilly and Company Limited, Windlesham,
Surrey, United Kingdom
OBJECTIVES: The National Institute for Clinical Excel-
lence in the UK encourage provision of health-related
quality of life (QoL) evidence for their assessments and
recently their guidance has ﬂagged the importance of
patient preference in therapy selection. Gemcitabine 
plus cisplatin (GC) displays comparable efﬁcacy to the
methotrexate, vinblastine, doxorubicin plus cisplatin
(MVAC) regimen in treating advanced bladder cancer but
shows signiﬁcant advantage in terms of tolerability and
serious adverse events. Therefore a UK study was con-
ducted to examine patient value associated with the tox-
icity proﬁle of GC, compared with MVAC. METHODS:
A novel application of discrete choice conjoint analysis
was employed to quantify preference and time-trade-off
utility differences providing sensitive strength of prefer-
